These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34165322)

  • 1. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [No Abstract]   [Full Text] [Related]  

  • 5. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 7. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
    Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
    Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
    De Velasco G; Xie W; Donskov F; Albiges L; Beuselinck B; Srinivas S; Agarwal N; Lee JL; Brugarolas J; Wood LA; Rha SY; Kollmannsberger C; North S; Kanesvaran R; Rini BI; Broom R; Yamamoto H; Kaymakcalan MD; Heng DYC; Choueiri TK
    Clin Genitourin Cancer; 2017 Jun; 15(3):403-410.e2. PubMed ID: 28254206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
    Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
    J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
    McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
    Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
    Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
    Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.